These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 17164690)
1. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Theisen FM; Haberhausen M; Schulz E; Fleischhaker C; Clement HW; Heinzel-Gutenbrunner M; Remschmidt H Ther Drug Monit; 2006 Dec; 28(6):750-9. PubMed ID: 17164690 [TBL] [Abstract][Full Text] [Related]
2. Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. Lu ML; Wu YX; Chen CH; Kuo PT; Chen YH; Lin CH; Wu TH PLoS One; 2016; 11(2):e0148539. PubMed ID: 26849777 [TBL] [Abstract][Full Text] [Related]
3. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia. Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417 [TBL] [Abstract][Full Text] [Related]
4. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. Lu ML; Lin CH; Chen YC; Yang HC; Wu TH PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510 [TBL] [Abstract][Full Text] [Related]
5. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Bachmann CJ; Haberhausen M; Heinzel-Gutenbrunner M; Remschmidt H; Theisen FM Ther Drug Monit; 2008 Feb; 30(1):108-12. PubMed ID: 18223472 [TBL] [Abstract][Full Text] [Related]
6. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Bergemann N; Frick A; Parzer P; Kopitz J Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613 [TBL] [Abstract][Full Text] [Related]
7. Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Haslemo T; Olsen K; Lunde H; Molden E Ther Drug Monit; 2012 Oct; 34(5):512-7. PubMed ID: 22972535 [TBL] [Abstract][Full Text] [Related]
8. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212 [TBL] [Abstract][Full Text] [Related]
9. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Skogh E; Sjödin I; Josefsson M; Dahl ML J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135 [TBL] [Abstract][Full Text] [Related]
10. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596 [TBL] [Abstract][Full Text] [Related]
11. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Crawford AM; Beasley CM; Tollefson GD Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336 [TBL] [Abstract][Full Text] [Related]
12. Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia. An H; Fan H; Chen S; Qi S; Ma B; Shi J; Wang Z; Yang F J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):255-259. PubMed ID: 33814547 [TBL] [Abstract][Full Text] [Related]
13. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Kassahun K; Mattiuz E; Nyhart E; Obermeyer B; Gillespie T; Murphy A; Goodwin RM; Tupper D; Callaghan JT; Lemberger L Drug Metab Dispos; 1997 Jan; 25(1):81-93. PubMed ID: 9010634 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Skogh E; Reis M; Dahl ML; Lundmark J; Bengtsson F Ther Drug Monit; 2002 Aug; 24(4):518-26. PubMed ID: 12142637 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Gex-Fabry M; Balant-Gorgia AE; Balant LP Ther Drug Monit; 2003 Feb; 25(1):46-53. PubMed ID: 12548144 [TBL] [Abstract][Full Text] [Related]
16. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Olesen OV; Linnet K Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059 [TBL] [Abstract][Full Text] [Related]
17. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553 [TBL] [Abstract][Full Text] [Related]
18. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Linnet K; Olesen OV Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636 [TBL] [Abstract][Full Text] [Related]
19. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Bachmann CJ; Rieger-Gies A; Heinzel-Gutenbrunner M; Hiemke C; Remschmidt H; Theisen FM Ther Drug Monit; 2008 Aug; 30(4):462-6. PubMed ID: 18641558 [TBL] [Abstract][Full Text] [Related]
20. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]